• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY:BMY)

    60.65 +0.92 (+1.54%)
    Official Closing Price Updated: 6:30 PM EDT, Mar 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bristol-Myers Squibb

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    88 89 Next >
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
    Via Finterra
    Topics Initial Public Offering
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
    Via MarketMinute
    News headline image
    Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
    From Bristol Myers Squibb
    Via Business Wire
    Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗
    Via Chartmill
    News headline image
    1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
    Via StockStory
    News headline image
    Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
    The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb
    Check out the companies making headlines yesterday: Robinhood (NASDAQ:HOOD): Financial services company Robinhood (NASDAQ:HOOD) rose by 4.8% on Wednesday aft... 
    Via StockStory
    News headline image
    Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
    As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Why Bristol-Myers Squibb (BMY) Stock Is Up Today
    What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after its positive momentum continued... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
    As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗
    This pair busts the myth of the sector being a desert for income investors. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
    Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
    Via MarketMinute
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗
    The healthcare company has been a top dividend growth stock for years. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
    In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
    Via MarketMinute
    News headline image
    Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗
    Sometimes "boring" is the way to go. 
    Via The Motley Fool
    Topics Economy Intellectual Property
    News headline image
    Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
    The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash ↗
    This pharma stock should hold up well if the market tanks. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million ↗
    This technology firm provides cloud-based compliance and reporting solutions for organizations with complex regulatory needs worldwide. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
    As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,... 
    Via MarketMinute
    Topics Earnings Economy Initial Public Offering
    News headline image
    Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
    Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    1 ETF That Could Turn $100 Per Month Into $67,380 ↗
    How does solid growth -- plus a 3.3% dividend yield sound? 
    Via The Motley Fool
    Topics ETFs Economy World Trade
    News headline image
    1 S&P 500 Stock Worth Your Attention and 2 We Question
    The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
    Via StockStory
    Topics Stocks
    News headline image
    BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
    In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
    Via MarketMinute
    News headline image
    3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
    A handful of the industry's income-generating gems are hiding in plain sight. 
    Via The Motley Fool
    News headline image
    Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
    From Bristol Myers Squibb
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    88 89 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.